Samantha Semenkow
Stock Analyst at Citigroup
(3.29)
# 2,821
Out of 5,182 analysts
79
Total ratings
43.28%
Success rate
5.47%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Samantha Semenkow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NKTR Nektar Therapeutics | Maintains: Buy | $123 → $151 | $91.68 | +64.70% | 3 | Apr 21, 2026 | |
| BHVN Biohaven | Maintains: Buy | $14 → $17 | $9.88 | +72.06% | 3 | Apr 2, 2026 | |
| BEAM Beam Therapeutics | Maintains: Buy | $64 → $68 | $27.11 | +150.83% | 4 | Mar 26, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $131 → $142 | $85.70 | +65.69% | 3 | Mar 20, 2026 | |
| BIOA BioAge Labs | Maintains: Buy | $15 → $52 | $17.05 | +204.99% | 6 | Mar 10, 2026 | |
| AGIO Agios Pharmaceuticals | Maintains: Buy | $38 → $46 | $25.32 | +81.67% | 2 | Mar 5, 2026 | |
| CPRX Catalyst Pharmaceuticals | Maintains: Buy | $33 → $35 | $27.37 | +27.88% | 4 | Mar 3, 2026 | |
| LRMR Larimar Therapeutics | Maintains: Buy | $12 → $14 | $4.54 | +208.37% | 7 | Feb 25, 2026 | |
| CGEM Cullinan Therapeutics | Initiates: Buy | $33 | $13.22 | +149.62% | 1 | Feb 17, 2026 | |
| ROIV Roivant Sciences | Maintains: Buy | $26 → $35 | $27.41 | +27.69% | 4 | Feb 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,124 → $1,091 | $780.25 | +39.83% | 8 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $15 | $14.49 | +0.07% | 2 | Dec 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $64 | $69.67 | -8.14% | 1 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $30 | $7.18 | +317.83% | 2 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $100 | $45.49 | +119.83% | 2 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5 → $4.25 | $3.70 | +14.86% | 5 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $5 | $17.18 | -70.90% | 3 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $10 | $2.95 | +238.98% | 4 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $2.31 | +73.16% | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $3.79 | +216.62% | 1 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $15 | $3.29 | +355.93% | 2 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $80 | $31.79 | +151.65% | 2 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $15 | $2.91 | +415.46% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $33 → $50 | $28.58 | +74.95% | 3 | Sep 27, 2023 |
Nektar Therapeutics
Apr 21, 2026
Maintains: Buy
Price Target: $123 → $151
Current: $91.68
Upside: +64.70%
Biohaven
Apr 2, 2026
Maintains: Buy
Price Target: $14 → $17
Current: $9.88
Upside: +72.06%
Beam Therapeutics
Mar 26, 2026
Maintains: Buy
Price Target: $64 → $68
Current: $27.11
Upside: +150.83%
Rhythm Pharmaceuticals
Mar 20, 2026
Maintains: Buy
Price Target: $131 → $142
Current: $85.70
Upside: +65.69%
BioAge Labs
Mar 10, 2026
Maintains: Buy
Price Target: $15 → $52
Current: $17.05
Upside: +204.99%
Agios Pharmaceuticals
Mar 5, 2026
Maintains: Buy
Price Target: $38 → $46
Current: $25.32
Upside: +81.67%
Catalyst Pharmaceuticals
Mar 3, 2026
Maintains: Buy
Price Target: $33 → $35
Current: $27.37
Upside: +27.88%
Larimar Therapeutics
Feb 25, 2026
Maintains: Buy
Price Target: $12 → $14
Current: $4.54
Upside: +208.37%
Cullinan Therapeutics
Feb 17, 2026
Initiates: Buy
Price Target: $33
Current: $13.22
Upside: +149.62%
Roivant Sciences
Feb 10, 2026
Maintains: Buy
Price Target: $26 → $35
Current: $27.41
Upside: +27.69%
Jan 8, 2026
Maintains: Buy
Price Target: $1,124 → $1,091
Current: $780.25
Upside: +39.83%
Dec 22, 2025
Downgrades: Neutral
Price Target: $17 → $15
Current: $14.49
Upside: +0.07%
Dec 17, 2025
Initiates: Buy
Price Target: $64
Current: $69.67
Upside: -8.14%
Dec 9, 2025
Maintains: Buy
Price Target: $16 → $30
Current: $7.18
Upside: +317.83%
Dec 9, 2025
Maintains: Buy
Price Target: $60 → $100
Current: $45.49
Upside: +119.83%
Nov 11, 2025
Maintains: Neutral
Price Target: $5 → $4.25
Current: $3.70
Upside: +14.86%
Oct 29, 2025
Downgrades: Sell
Price Target: $5
Current: $17.18
Upside: -70.90%
Aug 14, 2025
Maintains: Buy
Price Target: $13 → $10
Current: $2.95
Upside: +238.98%
May 15, 2025
Maintains: Buy
Price Target: $8 → $4
Current: $2.31
Upside: +73.16%
Dec 2, 2024
Initiates: Buy
Price Target: $12
Current: $3.79
Upside: +216.62%
Aug 9, 2024
Maintains: Buy
Price Target: $8 → $15
Current: $3.29
Upside: +355.93%
Jun 3, 2024
Reinstates: Buy
Price Target: $80
Current: $31.79
Upside: +151.65%
May 9, 2024
Maintains: Buy
Price Target: $16 → $15
Current: $2.91
Upside: +415.46%
Sep 27, 2023
Maintains: Buy
Price Target: $33 → $50
Current: $28.58
Upside: +74.95%